Global Serological Transplant Diagnostics Market By Offering (Terasaki T1, HLA Genotyping – Molecular typing kits, SSP typing and SeCore sequence-based typing products, Others, Antibody Detection – Screening and identification, Donor specific antibody identification, Single antigen and MICA kits, T2, T3 NIH method typing trays and monoclonal trays, Specific, ethnic, Supplemental and dry trays, others); By Technology (ELISA, xMAP, Others); By Application (SARS-CoV-2 Diagnosis and Surveillance, Post transplant Subclinical Acute or Acute rejection, Solid Organ Transplant Testing, Blood and Marrow Transplant, Others); By End User (Hospitals, Blood Banks and Transplant Centers, Donor registries and research laboratories, Human leukocyte antigen (HLA) Laboratories, Others); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Global serological transplant diagnostics market is growing at an estimated CAGR of 3% over the forecast period. Medical science today has answers to all the questions. Gone are the days when in case of any organ failure, there was no significant solution. But today, majority of organs that are damaged or failing can be easily replaced through the process of organ transplant. At the time of transplant, there are several things that are needed to be taken into consideration. The recipients who are expected to get a solid organ transplant or have been gone through the procedure are more vulnerable to fungal infections, in wake of the immunosuppressive treatment they are being rendered. There are three phases when it comes to post organ transplant. These phases are early, intermediate, and late, in all the phases, the individual is at risk of Candida infections. In wake of insufficiency of age-old tests, certain type of secondary diagnostic tests are being considered. One such type of tests are serological tests. These tests aid in diagnosing invasive candidiasis in those people who have received transplant in the form of liver or a kidney. These tests are emerging more popular each passing day and this is driving the growth of the global serological transplant diagnostics market.
The global serological transplant diagnostics market made massive money in the period of the coronavirus pandemic. The patients who were undergoing the treatment and were expected to receive a transplant were at high risk of being infected with the dreadful virus and in wake of this, the demand for serological transplant diagnostic tests skyrocketed.
Global Serological Transplant Diagnostics Market Revenue & Forecast, (US$ Million), 2022 – 2030
By Offering
On the basis of offering, the global serological transplant diagnostics market has been bifurcated into Terasaki T1, HLA genotyping, antibody detection, T2, T3 NIH method typing trays and monoclonal trays, specific, ethnic, supplemental and dry trays, and others. The HLA genotyping segment has been further bifurcated into molecular typing kits, SSP typing and SeCore sequence-based typing products and others. On the other hand, the antibody detection segment is divided ahead in screening and identification, donor specific antibody identification, and single antigen and MICA kits. Human leukocyte antigen (HLA) genotyping is used in order to match patients along with the donors for bone marrow or even in case of cord blood transplants. These antigens used happen to be proteins or markers that are discovered on majority of cells in the human body. The human immune system uses these markers for recognizing which cells belong in that body and which are foreigners.
By Technology
On the basis of technology, the global serological transplant diagnostics market has been bifurcated into ELISA, xMAP and others. xMAP or multi-analyte profiling technology happens to be a multiplex assay format that uses a panel of microspheres which basically are doped internally with two fluorescent dyes in order to create nearly 100 different bead identities. These identities can be used in different types of applications from this type of genotyping with the help of oligonucleotide probe hybridization to serological profiling.
By Application
On the basis of application, the global serological transplant diagnostics market has been divided into SARS-CoV-2 diagnosis and surveillance, post transplant subclinical acute or acute rejection, solid organ transplant testing, blood and marrow transplant and others. The solid organ transplant testing segment accounts for majority of revenue generated by this market. This is be0cause majority of people consider replacing organs after suffering from any sort of disease. People who have no issues spending money are happily opting for solid organ implant.
By End User
On the basis of the end user, the global serological transplant diagnostics market has been bifurcated into hospitals, blood banks and transplant centers, donor registries and laboratories, human leukocyte antigen (HLA) laboratories, and others. The human leukocyte antigen (HLA) laboratories segment mints most of the money for the market as this technique effectively helps the doctor diagnose any malfunction in the human body.
By Region
On the basis of region, the Global Serological Transplant Diagnostics Market has been divided into Latin America, Europe, North America, Asia-Pacific and others. The region of the North America has been dominating in terms of CAGR. Higher spending capacity of people in countries like the United States and Canada is the reason behind it.
Competitive Landscape
The report provides both, qualitative and quantitative research of global serological transplant diagnostics market as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contacts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the major players operating in the global serological transplant diagnostics market are listed below:
- Agena Bioscience
- AVIOQ
- BAG Healthcare
- BD
- Beckman Coulter
- Biogenuix
- Bio-Rad Laboratories, Inc.
- DIAGAST
- Grifols
- Hemo bioscience
- Immucor
- Siemens Healthineers
- ThermoFisher Scientific
- Other Market Participants
Global Serological Transplant Diagnostics Market
By Offering
- Terasaki T1
- HLA Genotyping
- Molecular typing kits
- SSP typing and SeCore sequence-based typing products
- Others
- Antibody Detection
- Screening and identification
- Donor specific antibody identification
- Single antigen and MICA kits
- T2
- T3 NIH method typing trays and monoclonal trays
- Specific, ethnic, Supplemental and dry trays
- Others
By Application
- SARS-CoV-2 Diagnosis and Surveillance
- Post transplant Subclinical Acute or Acute rejection
- Solid Organ Transplant Testing
- Blood and Marrow Transplant
- Others
By End User
- Hospitals
- Blood Banks and Transplant Centers
- Donor registries and research laboratories
- Human leukocyte antigen (HLA) Laboratories
- Others
By Region
- North America
- U.S
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1.
Market
Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2020
1.2.2. Base Year: 2021
1.2.3. Forecast Years: 2022 - 2030
2.
Key
Target Audiences
3.
Research
Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Serological Transplant Diagnostics Market
6.
Market
Synopsis: Serological Transplant
Diagnostics Market
7.
Serological
Transplant Diagnostics Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Serological Transplant Diagnostics
Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
Serological Transplant Diagnostics Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Serological Transplant
Diagnostics Market
8.
Global
Serological Transplant Diagnostics Market Analysis and Forecasts, 2022 - 2030
8.1. Overview
8.1.1. Global Serological Transplant Diagnostics
Market Revenue (US$ Mn)
8.2. Global Serological Transplant Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Offering
8.2.1. Terasaki T1
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.1.3.
Market
Forecast, 2022 - 2030
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1.
North
America
8.2.1.5.1.1. Market Estimation, 2015 - 2021
8.2.1.5.1.2. Market Forecast, 2022 - 2030
8.2.1.5.2.
Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2021
8.2.1.5.2.2. Market Forecast, 2022 - 2030
8.2.1.5.3.
Asia
Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2021
8.2.1.5.3.2. Market Forecast, 2022 - 2030
8.2.1.5.4.
Middle
East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2021
8.2.1.5.4.2. Market Forecast, 2022 - 2030
8.2.1.5.5.
Latin
America
8.2.1.5.5.1. Market Estimation, 2015 - 2021
8.2.1.5.5.2. Market Forecast, 2022 - 2030
8.2.2. HLA Genotyping (Definition, Market Estimation
and Penetration, 2015 - 2021, Market Estimation (2015 - 2021), Market Forecast
(2022 - 2030), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North
America, Europe, Asia Pacific, Middle East and Africa, Latin America) and
Information on Molecular typing kits, SSP typing and SeCore sequence-based
typing products, Others)
8.2.2.1.
Molecular
typing kits
8.2.2.2.
SSP
typing and SeCore sequence-based typing products
8.2.2.3.
Others
8.2.3. Antibody Detection (Definition, Market
Estimation and Penetration, 2015 - 2021, Market Estimation (2015 - 2021),
Market Forecast (2022 - 2030), Compound Annual Growth Rate (CAGR), Regional
Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin
America) and Information on Screening and identification, Donor specific
antibody identification, Single antigen and MICA kits)
8.2.3.1.
Screening
and identification
8.2.3.2.
Donor
specific antibody identification
8.2.3.3.
Single
antigen and MICA kits
8.2.4. T2
8.2.4.1.
Definition
8.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.4.3.
Market
Forecast, 2022 - 2030
8.2.4.4.
Compound
Annual Growth Rate (CAGR)
8.2.4.5.
Regional
Bifurcation
8.2.4.5.1.
North
America
8.2.4.5.1.1. Market Estimation, 2015 - 2021
8.2.4.5.1.2. Market Forecast, 2022 - 2030
8.2.4.5.2.
Europe
8.2.4.5.2.1. Market Estimation, 2015 - 2021
8.2.4.5.2.2. Market Forecast, 2022 - 2030
8.2.4.5.3.
Asia
Pacific
8.2.4.5.3.1. Market Estimation, 2015 - 2021
8.2.4.5.3.2. Market Forecast, 2022 - 2030
8.2.4.5.4.
Middle
East and Africa
8.2.4.5.4.1. Market Estimation, 2015 - 2021
8.2.4.5.4.2. Market Forecast, 2022 - 2030
8.2.4.5.5.
Latin
America
8.2.4.5.5.1. Market Estimation, 2015 - 2021
8.2.4.5.5.2. Market Forecast, 2022 - 2030
8.2.5. T3 NIH method typing trays and monoclonal
trays
8.2.5.1.
Definition
8.2.5.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.5.3.
Market
Forecast, 2022 - 2030
8.2.5.4.
Compound
Annual Growth Rate (CAGR)
8.2.5.5.
Regional
Bifurcation
8.2.5.5.1.
North
America
8.2.5.5.1.1. Market Estimation, 2015 - 2021
8.2.5.5.1.2. Market Forecast, 2022 - 2030
8.2.5.5.2.
Europe
8.2.5.5.2.1. Market Estimation, 2015 - 2021
8.2.5.5.2.2. Market Forecast, 2022 - 2030
8.2.5.5.3.
Asia
Pacific
8.2.5.5.3.1. Market Estimation, 2015 - 2021
8.2.5.5.3.2. Market Forecast, 2022 - 2030
8.2.5.5.4.
Middle
East and Africa
8.2.5.5.4.1. Market Estimation, 2015 - 2021
8.2.5.5.4.2. Market Forecast, 2022 - 2030
8.2.5.5.5.
Latin
America
8.2.5.5.5.1. Market Estimation, 2015 - 2021
8.2.5.5.5.2. Market Forecast, 2022 - 2030
8.2.6. Specific, ethnic, Supplemental and dry trays
8.2.6.1.
Definition
8.2.6.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.6.3.
Market
Forecast, 2022 - 2030
8.2.6.4.
Compound
Annual Growth Rate (CAGR)
8.2.6.5.
Regional
Bifurcation
8.2.6.5.1.
North
America
8.2.6.5.1.1. Market Estimation, 2015 - 2021
8.2.6.5.1.2. Market Forecast, 2022 - 2030
8.2.6.5.2.
Europe
8.2.6.5.2.1. Market Estimation, 2015 - 2021
8.2.6.5.2.2. Market Forecast, 2022 - 2030
8.2.6.5.3.
Asia
Pacific
8.2.6.5.3.1. Market Estimation, 2015 - 2021
8.2.6.5.3.2. Market Forecast, 2022 - 2030
8.2.6.5.4.
Middle
East and Africa
8.2.6.5.4.1. Market Estimation, 2015 - 2021
8.2.6.5.4.2. Market Forecast, 2022 - 2030
8.2.6.5.5.
Latin
America
8.2.6.5.5.1. Market Estimation, 2015 - 2021
8.2.6.5.5.2. Market Forecast, 2022 - 2030
8.2.7. Others
8.2.7.1.
Definition
8.2.7.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.7.3.
Market
Forecast, 2022 - 2030
8.2.7.4.
Compound
Annual Growth Rate (CAGR)
8.2.7.5.
Regional
Bifurcation
8.2.7.5.1.
North
America
8.2.7.5.1.1. Market Estimation, 2015 - 2021
8.2.7.5.1.2. Market Forecast, 2022 - 2030
8.2.7.5.2.
Europe
8.2.7.5.2.1. Market Estimation, 2015 - 2021
8.2.7.5.2.2. Market Forecast, 2022 - 2030
8.2.7.5.3.
Asia
Pacific
8.2.7.5.3.1. Market Estimation, 2015 - 2021
8.2.7.5.3.2. Market Forecast, 2022 - 2030
8.2.7.5.4.
Middle
East and Africa
8.2.7.5.4.1. Market Estimation, 2015 - 2021
8.2.7.5.4.2. Market Forecast, 2022 - 2030
8.2.7.5.5.
Latin
America
8.2.7.5.5.1. Market Estimation, 2015 - 2021
8.2.7.5.5.2. Market Forecast, 2022 - 2030
8.3. Key Segment for Channeling Investments
8.3.1. By Offering
9.
Global
Serological Transplant Diagnostics Market Analysis and Forecasts, 2022 - 2030
9.1. Overview
9.2. Global Serological Transplant Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Application
9.2.1. SARS-CoV-2 Diagnosis and Surveillance
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.1.3.
Market
Forecast, 2022 - 2030
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1.
North
America
9.2.1.5.1.1. Market Estimation, 2015 - 2021
9.2.1.5.1.2. Market Forecast, 2022 - 2030
9.2.1.5.2.
Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2021
9.2.1.5.2.2. Market Forecast, 2022 - 2030
9.2.1.5.3.
Asia
Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2021
9.2.1.5.3.2. Market Forecast, 2022 - 2030
9.2.1.5.4.
Middle
East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2021
9.2.1.5.4.2. Market Forecast, 2022 - 2030
9.2.1.5.5.
Latin
America
9.2.1.5.5.1. Market Estimation, 2015 - 2021
9.2.1.5.5.2. Market Forecast, 2022 - 2030
9.2.2. Post transplant Subclinical Acute or Acute
rejection
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.2.3.
Market
Forecast, 2022 - 2030
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1.
North
America
9.2.2.5.1.1. Market Estimation, 2015 - 2021
9.2.2.5.1.2. Market Forecast, 2022 - 2030
9.2.2.5.2.
Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2021
9.2.2.5.2.2. Market Forecast, 2022 - 2030
9.2.2.5.3.
Asia
Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2021
9.2.2.5.3.2. Market Forecast, 2022 - 2030
9.2.2.5.4.
Middle
East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2021
9.2.2.5.4.2. Market Forecast, 2022 - 2030
9.2.2.5.5.
Latin
America
9.2.2.5.5.1. Market Estimation, 2015 - 2021
9.2.2.5.5.2. Market Forecast, 2022 - 2030
9.2.3. Solid Organ Transplant Testing
9.2.3.1.
Definition
9.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.3.3.
Market
Forecast, 2022 - 2030
9.2.3.4.
Compound
Annual Growth Rate (CAGR)
9.2.3.5.
Regional
Bifurcation
9.2.3.5.1.
North
America
9.2.3.5.1.1. Market Estimation, 2015 - 2021
9.2.3.5.1.2. Market Forecast, 2022 - 2030
9.2.3.5.2.
Europe
9.2.3.5.2.1. Market Estimation, 2015 - 2021
9.2.3.5.2.2. Market Forecast, 2022 - 2030
9.2.3.5.3.
Asia
Pacific
9.2.3.5.3.1. Market Estimation, 2015 - 2021
9.2.3.5.3.2. Market Forecast, 2022 - 2030
9.2.3.5.4.
Middle
East and Africa
9.2.3.5.4.1. Market Estimation, 2015 - 2021
9.2.3.5.4.2. Market Forecast, 2022 - 2030
9.2.3.5.5.
Latin
America
9.2.3.5.5.1. Market Estimation, 2015 - 2021
9.2.3.5.5.2. Market Forecast, 2022 - 2030
9.2.4. Blood and Marrow Transplant
9.2.4.1.
Definition
9.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.4.3.
Market
Forecast, 2022 - 2030
9.2.4.4.
Compound
Annual Growth Rate (CAGR)
9.2.4.5.
Regional
Bifurcation
9.2.4.5.1.
North
America
9.2.4.5.1.1. Market Estimation, 2015 - 2021
9.2.4.5.1.2. Market Forecast, 2022 - 2030
9.2.4.5.2.
Europe
9.2.4.5.2.1. Market Estimation, 2015 - 2021
9.2.4.5.2.2. Market Forecast, 2022 - 2030
9.2.4.5.3.
Asia
Pacific
9.2.4.5.3.1. Market Estimation, 2015 - 2021
9.2.4.5.3.2. Market Forecast, 2022 - 2030
9.2.4.5.4.
Middle
East and Africa
9.2.4.5.4.1. Market Estimation, 2015 - 2021
9.2.4.5.4.2. Market Forecast, 2022 - 2030
9.2.4.5.5.
Latin
America
9.2.4.5.5.1. Market Estimation, 2015 - 2021
9.2.4.5.5.2. Market Forecast, 2022 - 2030
9.2.5. Others
9.2.5.1.
Definition
9.2.5.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.5.3.
Market
Forecast, 2022 - 2030
9.2.5.4.
Compound
Annual Growth Rate (CAGR)
9.2.5.5.
Regional
Bifurcation
9.2.5.5.1.
North
America
9.2.5.5.1.1. Market Estimation, 2015 - 2021
9.2.5.5.1.2. Market Forecast, 2022 - 2030
9.2.5.5.2.
Europe
9.2.5.5.2.1. Market Estimation, 2015 - 2021
9.2.5.5.2.2. Market Forecast, 2022 - 2030
9.2.5.5.3.
Asia
Pacific
9.2.5.5.3.1. Market Estimation, 2015 - 2021
9.2.5.5.3.2. Market Forecast, 2022 - 2030
9.2.5.5.4.
Middle
East and Africa
9.2.5.5.4.1. Market Estimation, 2015 - 2021
9.2.5.5.4.2. Market Forecast, 2022 - 2030
9.2.5.5.5.
Latin
America
9.2.5.5.5.1. Market Estimation, 2015 - 2021
9.2.5.5.5.2. Market Forecast, 2022 - 2030
9.3. Key Segment for Channeling Investments
9.3.1. By Application
10. Global Serological Transplant Diagnostics
Market Analysis and Forecasts, 2022 - 2030
10.1. Overview
10.2. Global Serological Transplant Diagnostics
Market Revenue (US$ Mn) and Forecasts, By End User
10.2.1. Hospitals
10.2.1.1.
Definition
10.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.1.3.
Market
Forecast, 2022 - 2030
10.2.1.4.
Compound
Annual Growth Rate (CAGR)
10.2.1.5.
Regional
Bifurcation
10.2.1.5.1.
North
America
10.2.1.5.1.1. Market Estimation, 2015 - 2021
10.2.1.5.1.2. Market Forecast, 2022 - 2030
10.2.1.5.2.
Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2021
10.2.1.5.2.2. Market Forecast, 2022 - 2030
10.2.1.5.3.
Asia
Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2021
10.2.1.5.3.2. Market Forecast, 2022 - 2030
10.2.1.5.4.
Middle
East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2021
10.2.1.5.4.2. Market Forecast, 2022 - 2030
10.2.1.5.5.
Latin
America
10.2.1.5.5.1. Market Estimation, 2015 - 2021
10.2.1.5.5.2. Market Forecast, 2022 - 2030
10.2.2. Blood Banks and Transplant Centers
10.2.2.1.
Definition
10.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.2.3.
Market
Forecast, 2022 - 2030
10.2.2.4.
Compound
Annual Growth Rate (CAGR)
10.2.2.5.
Regional
Bifurcation
10.2.2.5.1.
North
America
10.2.2.5.1.1. Market Estimation, 2015 - 2021
10.2.2.5.1.2. Market Forecast, 2022 - 2030
10.2.2.5.2.
Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2021
10.2.2.5.2.2. Market Forecast, 2022 - 2030
10.2.2.5.3.
Asia
Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2021
10.2.2.5.3.2. Market Forecast, 2022 - 2030
10.2.2.5.4.
Middle
East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2021
10.2.2.5.4.2. Market Forecast, 2022 - 2030
10.2.2.5.5.
Latin
America
10.2.2.5.5.1. Market Estimation, 2015 - 2021
10.2.2.5.5.2. Market Forecast, 2022 - 2030
10.2.3. Donor registries and research laboratories
10.2.3.1.
Definition
10.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.3.3.
Market
Forecast, 2022 - 2030
10.2.3.4.
Compound
Annual Growth Rate (CAGR)
10.2.3.5.
Regional
Bifurcation
10.2.3.5.1.
North
America
10.2.3.5.1.1. Market Estimation, 2015 - 2021
10.2.3.5.1.2. Market Forecast, 2022 - 2030
10.2.3.5.2.
Europe
10.2.3.5.2.1. Market Estimation, 2015 - 2021
10.2.3.5.2.2. Market Forecast, 2022 - 2030
10.2.3.5.3.
Asia
Pacific
10.2.3.5.3.1. Market Estimation, 2015 - 2021
10.2.3.5.3.2. Market Forecast, 2022 - 2030
10.2.3.5.4.
Middle
East and Africa
10.2.3.5.4.1. Market Estimation, 2015 - 2021
10.2.3.5.4.2. Market Forecast, 2022 - 2030
10.2.3.5.5.
Latin
America
10.2.3.5.5.1. Market Estimation, 2015 - 2021
10.2.3.5.5.2. Market Forecast, 2022 - 2030
10.2.4. Human leukocyte antigen (HLA) Laboratories
10.2.4.1.
Definition
10.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.4.3.
Market
Forecast, 2022 - 2030
10.2.4.4.
Compound
Annual Growth Rate (CAGR)
10.2.4.5.
Regional
Bifurcation
10.2.4.5.1.
North
America
10.2.4.5.1.1. Market Estimation, 2015 - 2021
10.2.4.5.1.2. Market Forecast, 2022 - 2030
10.2.4.5.2.
Europe
10.2.4.5.2.1. Market Estimation, 2015 - 2021
10.2.4.5.2.2. Market Forecast, 2022 - 2030
10.2.4.5.3.
Asia
Pacific
10.2.4.5.3.1. Market Estimation, 2015 - 2021
10.2.4.5.3.2. Market Forecast, 2022 - 2030
10.2.4.5.4.
Middle
East and Africa
10.2.4.5.4.1. Market Estimation, 2015 - 2021
10.2.4.5.4.2. Market Forecast, 2022 - 2030
10.2.4.5.5.
Latin
America
10.2.4.5.5.1. Market Estimation, 2015 - 2021
10.2.4.5.5.2. Market Forecast, 2022 - 2030
10.2.5. Others
10.2.5.1.
Definition
10.2.5.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.5.3.
Market
Forecast, 2022 - 2030
10.2.5.4.
Compound
Annual Growth Rate (CAGR)
10.2.5.5.
Regional
Bifurcation
10.2.5.5.1.
North
America
10.2.5.5.1.1. Market Estimation, 2015 - 2021
10.2.5.5.1.2. Market Forecast, 2022 - 2030
10.2.5.5.2.
Europe
10.2.5.5.2.1. Market Estimation, 2015 - 2021
10.2.5.5.2.2. Market Forecast, 2022 - 2030
10.2.5.5.3.
Asia
Pacific
10.2.5.5.3.1. Market Estimation, 2015 - 2021
10.2.5.5.3.2. Market Forecast, 2022 - 2030
10.2.5.5.4.
Middle
East and Africa
10.2.5.5.4.1. Market Estimation, 2015 - 2021
10.2.5.5.4.2. Market Forecast, 2022 - 2030
10.2.5.5.5.
Latin
America
10.2.5.5.5.1. Market Estimation, 2015 - 2021
10.2.5.5.5.2. Market Forecast, 2022 - 2030
10.3. Key Segment for Channeling Investments
10.3.1. By End User
11. North America Serological Transplant
Diagnostics Market Analysis and Forecasts, 2022 - 2030
11.1. Overview
11.1.1. North America Serological Transplant
Diagnostics Market Revenue (US$ Mn)
11.2. North America Serological Transplant
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offering
11.2.1. Terasaki T1
11.2.2. HLA Genotyping
11.2.2.1.
Molecular
typing kits
11.2.2.2.
SSP
typing and SeCore sequence-based typing products
11.2.2.3.
Others
11.2.3. Antibody Detection
11.2.3.1.
Screening
and identification
11.2.3.2.
Donor
specific antibody identification
11.2.3.3.
Single
antigen and MICA kits
11.2.4. T2
11.2.5. T3 NIH method typing trays and monoclonal
trays
11.2.6. Specific, ethnic, Supplemental and dry trays
11.2.7. Others
11.3. North America Serological Transplant
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
11.3.1. SARS-CoV-2 Diagnosis and Surveillance
11.3.2. Post transplant Subclinical Acute or Acute
rejection
11.3.3. Solid Organ Transplant Testing
11.3.4. Blood and Marrow Transplant
11.3.5. Others
11.4. North America Serological Transplant
Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
11.4.1. Hospitals
11.4.2. Blood Banks and Transplant Centers
11.4.3. Donor registries and research laboratories
11.4.4. Human leukocyte antigen (HLA) Laboratories
11.4.5. Others
11.5. North America Serological Transplant
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
11.5.1. U.S
11.5.1.1.
U.S
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Offering
11.5.1.1.1.
Terasaki
T1
11.5.1.1.2.
HLA
Genotyping
11.5.1.1.2.1. Molecular typing kits
11.5.1.1.2.2. SSP typing and SeCore sequence-based typing
products
11.5.1.1.2.3. Others
11.5.1.1.3.
Antibody
Detection
11.5.1.1.3.1. Screening and identification
11.5.1.1.3.2. Donor specific antibody identification
11.5.1.1.3.3. Single antigen and MICA kits
11.5.1.1.4.
T2
11.5.1.1.5.
T3 NIH
method typing trays and monoclonal trays
11.5.1.1.6.
Specific,
ethnic, Supplemental and dry trays
11.5.1.1.7.
Others
11.5.1.2.
U.S
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
11.5.1.2.1.
SARS-CoV-2
Diagnosis and Surveillance
11.5.1.2.2.
Post
transplant Subclinical Acute or Acute rejection
11.5.1.2.3.
Solid
Organ Transplant Testing
11.5.1.2.4.
Blood
and Marrow Transplant
11.5.1.2.5.
Others
11.5.1.3.
U.S
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
End User
11.5.1.3.1.
Hospitals
11.5.1.3.2.
Blood
Banks and Transplant Centers
11.5.1.3.3.
Donor
registries and research laboratories
11.5.1.3.4.
Human
leukocyte antigen (HLA) Laboratories
11.5.1.3.5.
Others
11.5.2. Canada
11.5.2.1.
Canada
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Offering
11.5.2.1.1.
Terasaki
T1
11.5.2.1.2.
HLA
Genotyping
11.5.2.1.2.1. Molecular typing kits
11.5.2.1.2.2. SSP typing and SeCore sequence-based typing
products
11.5.2.1.2.3. Others
11.5.2.1.3.
Antibody
Detection
11.5.2.1.3.1. Screening and identification
11.5.2.1.3.2. Donor specific antibody identification
11.5.2.1.3.3. Single antigen and MICA kits
11.5.2.1.4.
T2
11.5.2.1.5.
T3 NIH
method typing trays and monoclonal trays
11.5.2.1.6.
Specific,
ethnic, Supplemental and dry trays
11.5.2.1.7.
Others
11.5.2.2.
Canada
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
11.5.2.2.1.
SARS-CoV-2
Diagnosis and Surveillance
11.5.2.2.2.
Post
transplant Subclinical Acute or Acute rejection
11.5.2.2.3.
Solid
Organ Transplant Testing
11.5.2.2.4.
Blood
and Marrow Transplant
11.5.2.2.5.
Others
11.5.2.3.
Canada
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
End User
11.5.2.3.1.
Hospitals
11.5.2.3.2.
Blood
Banks and Transplant Centers
11.5.2.3.3.
Donor
registries and research laboratories
11.5.2.3.4.
Human
leukocyte antigen (HLA) Laboratories
11.5.2.3.5.
Others
11.5.3. Mexico
11.5.3.1.
Mexico
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Offering
11.5.3.1.1.
Terasaki
T1
11.5.3.1.2.
HLA
Genotyping
11.5.3.1.2.1. Molecular typing kits
11.5.3.1.2.2. SSP typing and SeCore sequence-based typing
products
11.5.3.1.2.3. Others
11.5.3.1.3.
Antibody
Detection
11.5.3.1.3.1. Screening and identification
11.5.3.1.3.2. Donor specific antibody identification
11.5.3.1.3.3. Single antigen and MICA kits
11.5.3.1.4.
T2
11.5.3.1.5.
T3 NIH
method typing trays and monoclonal trays
11.5.3.1.6.
Specific,
ethnic, Supplemental and dry trays
11.5.3.1.7.
Others
11.5.3.2.
Mexico
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
11.5.3.2.1.
SARS-CoV-2
Diagnosis and Surveillance
11.5.3.2.2.
Post
transplant Subclinical Acute or Acute rejection
11.5.3.2.3.
Solid
Organ Transplant Testing
11.5.3.2.4.
Blood
and Marrow Transplant
11.5.3.2.5.
Others
11.5.3.3.
Mexico
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
End User
11.5.3.3.1.
Hospitals
11.5.3.3.2.
Blood
Banks and Transplant Centers
11.5.3.3.3.
Donor
registries and research laboratories
11.5.3.3.4.
Human
leukocyte antigen (HLA) Laboratories
11.5.3.3.5.
Others
11.5.4. Rest of North America
11.5.4.1.
Rest of
North America Serological Transplant Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offering
11.5.4.1.1.
Terasaki
T1
11.5.4.1.2.
HLA
Genotyping
11.5.4.1.2.1. Molecular typing kits
11.5.4.1.2.2. SSP typing and SeCore sequence-based typing
products
11.5.4.1.2.3. Others
11.5.4.1.3.
Antibody
Detection
11.5.4.1.3.1. Screening and identification
11.5.4.1.3.2. Donor specific antibody identification
11.5.4.1.3.3. Single antigen and MICA kits
11.5.4.1.4.
T2
11.5.4.1.5.
T3 NIH
method typing trays and monoclonal trays
11.5.4.1.6.
Specific,
ethnic, Supplemental and dry trays
11.5.4.1.7.
Others
11.5.4.2.
Rest of
North America Serological Transplant Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Application
11.5.4.2.1.
SARS-CoV-2
Diagnosis and Surveillance
11.5.4.2.2.
Post
transplant Subclinical Acute or Acute rejection
11.5.4.2.3.
Solid
Organ Transplant Testing
11.5.4.2.4.
Blood
and Marrow Transplant
11.5.4.2.5.
Others
11.5.4.3.
Rest of
North America Serological Transplant Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End User
11.5.4.3.1.
Hospitals
11.5.4.3.2.
Blood
Banks and Transplant Centers
11.5.4.3.3.
Donor
registries and research laboratories
11.5.4.3.4.
Human
leukocyte antigen (HLA) Laboratories
11.5.4.3.5.
Others
11.6. Key Segment for Channeling Investments
11.6.1. By Country
11.6.2. By Offering
11.6.3. By Application
11.6.4. By End User
12. Europe Serological Transplant Diagnostics
Market Analysis and Forecasts, 2022 - 2030
12.1. Overview
12.1.1. Europe Serological Transplant Diagnostics
Market Revenue (US$ Mn)
12.2. Europe Serological Transplant Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Offering
12.2.1. Terasaki T1
12.2.2. HLA Genotyping
12.2.2.1.
Molecular
typing kits
12.2.2.2.
SSP
typing and SeCore sequence-based typing products
12.2.2.3.
Others
12.2.3. Antibody Detection
12.2.3.1.
Screening
and identification
12.2.3.2.
Donor
specific antibody identification
12.2.3.3.
Single
antigen and MICA kits
12.2.4. T2
12.2.5. T3 NIH method typing trays and monoclonal
trays
12.2.6. Specific, ethnic, Supplemental and dry trays
12.2.7. Others
12.3. Europe Serological Transplant Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Application
12.3.1. SARS-CoV-2 Diagnosis and Surveillance
12.3.2. Post transplant Subclinical Acute or Acute
rejection
12.3.3. Solid Organ Transplant Testing
12.3.4. Blood and Marrow Transplant
12.3.5. Others
12.4. Europe Serological Transplant Diagnostics
Market Revenue (US$ Mn) and Forecasts, By End User
12.4.1. Hospitals
12.4.2. Blood Banks and Transplant Centers
12.4.3. Donor registries and research laboratories
12.4.4. Human leukocyte antigen (HLA) Laboratories
12.4.5. Others
12.5. Europe Serological Transplant Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1.
France
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Offering
12.5.1.1.1.
Terasaki
T1
12.5.1.1.2.
HLA
Genotyping
12.5.1.1.2.1. Molecular typing kits
12.5.1.1.2.2. SSP typing and SeCore sequence-based typing
products
12.5.1.1.2.3. Others
12.5.1.1.3.
Antibody
Detection
12.5.1.1.3.1. Screening and identification
12.5.1.1.3.2. Donor specific antibody identification
12.5.1.1.3.3. Single antigen and MICA kits
12.5.1.1.4.
T2
12.5.1.1.5.
T3 NIH
method typing trays and monoclonal trays
12.5.1.1.6.
Specific,
ethnic, Supplemental and dry trays
12.5.1.1.7.
Others
12.5.1.2.
France
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
12.5.1.2.1.
SARS-CoV-2
Diagnosis and Surveillance
12.5.1.2.2.
Post
transplant Subclinical Acute or Acute rejection
12.5.1.2.3.
Solid
Organ Transplant Testing
12.5.1.2.4.
Blood
and Marrow Transplant
12.5.1.2.5.
Others
12.5.1.3.
France
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
End User
12.5.1.3.1.
Hospitals
12.5.1.3.2.
Blood
Banks and Transplant Centers
12.5.1.3.3.
Donor
registries and research laboratories
12.5.1.3.4.
Human
leukocyte antigen (HLA) Laboratories
12.5.1.3.5.
Others
12.5.2. The UK
12.5.2.1.
The UK
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Offering
12.5.2.1.1.
Terasaki
T1
12.5.2.1.2.
HLA
Genotyping
12.5.2.1.2.1. Molecular typing kits
12.5.2.1.2.2. SSP typing and SeCore sequence-based typing
products
12.5.2.1.2.3. Others
12.5.2.1.3.
Antibody
Detection
12.5.2.1.3.1. Screening and identification
12.5.2.1.3.2. Donor specific antibody identification
12.5.2.1.3.3. Single antigen and MICA kits
12.5.2.1.4.
T2
12.5.2.1.5.
T3 NIH
method typing trays and monoclonal trays
12.5.2.1.6.
Specific,
ethnic, Supplemental and dry trays
12.5.2.1.7.
Others
12.5.2.2.
The UK
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
12.5.2.2.1.
SARS-CoV-2
Diagnosis and Surveillance
12.5.2.2.2.
Post
transplant Subclinical Acute or Acute rejection
12.5.2.2.3.
Solid
Organ Transplant Testing
12.5.2.2.4.
Blood
and Marrow Transplant
12.5.2.2.5.
Others
12.5.2.3.
The UK
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
End User
12.5.2.3.1.
Hospitals
12.5.2.3.2.
Blood
Banks and Transplant Centers
12.5.2.3.3.
Donor
registries and research laboratories
12.5.2.3.4.
Human
leukocyte antigen (HLA) Laboratories
12.5.2.3.5.
Others
12.5.3. Spain
12.5.3.1.
Spain
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Offering
12.5.3.1.1.
Terasaki
T1
12.5.3.1.2.
HLA
Genotyping
12.5.3.1.2.1. Molecular typing kits
12.5.3.1.2.2. SSP typing and SeCore sequence-based typing
products
12.5.3.1.2.3. Others
12.5.3.1.3.
Antibody
Detection
12.5.3.1.3.1. Screening and identification
12.5.3.1.3.2. Donor specific antibody identification
12.5.3.1.3.3. Single antigen and MICA kits
12.5.3.1.4.
T2
12.5.3.1.5.
T3 NIH
method typing trays and monoclonal trays
12.5.3.1.6.
Specific,
ethnic, Supplemental and dry trays
12.5.3.1.7.
Others
12.5.3.2.
Spain
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
12.5.3.2.1.
SARS-CoV-2
Diagnosis and Surveillance
12.5.3.2.2.
Post
transplant Subclinical Acute or Acute rejection
12.5.3.2.3.
Solid
Organ Transplant Testing
12.5.3.2.4.
Blood
and Marrow Transplant
12.5.3.2.5.
Others
12.5.3.3.
Spain
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
End User
12.5.3.3.1.
Hospitals
12.5.3.3.2.
Blood
Banks and Transplant Centers
12.5.3.3.3.
Donor
registries and research laboratories
12.5.3.3.4.
Human
leukocyte antigen (HLA) Laboratories
12.5.3.3.5.
Others
12.5.4. Germany
12.5.4.1.
Germany
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Offering
12.5.4.1.1.
Terasaki
T1
12.5.4.1.2.
HLA
Genotyping
12.5.4.1.2.1. Molecular typing kits
12.5.4.1.2.2. SSP typing and SeCore sequence-based typing
products
12.5.4.1.2.3. Others
12.5.4.1.3.
Antibody
Detection
12.5.4.1.3.1. Screening and identification
12.5.4.1.3.2. Donor specific antibody identification
12.5.4.1.3.3. Single antigen and MICA kits
12.5.4.1.4.
T2
12.5.4.1.5.
T3 NIH
method typing trays and monoclonal trays
12.5.4.1.6.
Specific,
ethnic, Supplemental and dry trays
12.5.4.1.7.
Others
12.5.4.2.
Germany
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
12.5.4.2.1.
SARS-CoV-2
Diagnosis and Surveillance
12.5.4.2.2.
Post
transplant Subclinical Acute or Acute rejection
12.5.4.2.3.
Solid
Organ Transplant Testing
12.5.4.2.4.
Blood
and Marrow Transplant
12.5.4.2.5.
Others
12.5.4.3.
Germany
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
End User
12.5.4.3.1.
Hospitals
12.5.4.3.2.
Blood
Banks and Transplant Centers
12.5.4.3.3.
Donor
registries and research laboratories
12.5.4.3.4.
Human
leukocyte antigen (HLA) Laboratories
12.5.4.3.5.
Others
12.5.5. Italy
12.5.5.1.
Italy
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Offering
12.5.5.1.1.
Terasaki
T1
12.5.5.1.2.
HLA
Genotyping
12.5.5.1.2.1. Molecular typing kits
12.5.5.1.2.2. SSP typing and SeCore sequence-based typing
products
12.5.5.1.2.3. Others
12.5.5.1.3.
Antibody
Detection
12.5.5.1.3.1. Screening and identification
12.5.5.1.3.2. Donor specific antibody identification
12.5.5.1.3.3. Single antigen and MICA kits
12.5.5.1.4.
T2
12.5.5.1.5.
T3 NIH
method typing trays and monoclonal trays
12.5.5.1.6.
Specific,
ethnic, Supplemental and dry trays
12.5.5.1.7.
Others
12.5.5.2.
Italy
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
12.5.5.2.1.
SARS-CoV-2
Diagnosis and Surveillance
12.5.5.2.2.
Post
transplant Subclinical Acute or Acute rejection
12.5.5.2.3.
Solid
Organ Transplant Testing
12.5.5.2.4.
Blood
and Marrow Transplant
12.5.5.2.5.
Others
12.5.5.3.
Italy
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
End User
12.5.5.3.1.
Hospitals
12.5.5.3.2.
Blood
Banks and Transplant Centers
12.5.5.3.3.
Donor
registries and research laboratories
12.5.5.3.4.
Human leukocyte
antigen (HLA) Laboratories
12.5.5.3.5.
Others
12.5.6. Nordic Countries
12.5.6.1.
Nordic
Countries Serological Transplant Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offering
12.5.6.1.1.
Terasaki
T1
12.5.6.1.2.
HLA
Genotyping
12.5.6.1.2.1. Molecular typing kits
12.5.6.1.2.2. SSP typing and SeCore sequence-based typing
products
12.5.6.1.2.3. Others
12.5.6.1.3.
Antibody
Detection
12.5.6.1.3.1. Screening and identification
12.5.6.1.3.2. Donor specific antibody identification
12.5.6.1.3.3. Single antigen and MICA kits
12.5.6.1.4.
T2
12.5.6.1.5.
T3 NIH
method typing trays and monoclonal trays
12.5.6.1.6.
Specific,
ethnic, Supplemental and dry trays
12.5.6.1.7.
Others
12.5.6.2.
Nordic
Countries Serological Transplant Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Application
12.5.6.2.1.
SARS-CoV-2
Diagnosis and Surveillance
12.5.6.2.2.
Post
transplant Subclinical Acute or Acute rejection
12.5.6.2.3.
Solid
Organ Transplant Testing
12.5.6.2.4.
Blood
and Marrow Transplant
12.5.6.2.5.
Others
12.5.6.3.
Nordic
Countries Serological Transplant Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End User
12.5.6.3.1.
Hospitals
12.5.6.3.2.
Blood
Banks and Transplant Centers
12.5.6.3.3.
Donor
registries and research laboratories
12.5.6.3.4.
Human
leukocyte antigen (HLA) Laboratories
12.5.6.3.5.
Others
12.5.6.4.
Nordic
Countries Serological Transplant Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Country
12.5.6.4.1.
Denmark
12.5.6.4.2.
Finland
12.5.6.4.3.
Iceland
12.5.6.4.4.
Sweden
12.5.6.4.5.
Norway
12.5.7. Benelux Union
12.5.7.1.
Benelux
Union Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts,
By Offering
12.5.7.1.1.
Terasaki
T1
12.5.7.1.2.
HLA
Genotyping
12.5.7.1.2.1. Molecular typing kits
12.5.7.1.2.2. SSP typing and SeCore sequence-based typing
products
12.5.7.1.2.3. Others
12.5.7.1.3.
Antibody
Detection
12.5.7.1.3.1. Screening and identification
12.5.7.1.3.2. Donor specific antibody identification
12.5.7.1.3.3. Single antigen and MICA kits
12.5.7.1.4.
T2
12.5.7.1.5.
T3 NIH
method typing trays and monoclonal trays
12.5.7.1.6.
Specific,
ethnic, Supplemental and dry trays
12.5.7.1.7.
Others
12.5.7.2.
Benelux
Union Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts,
By Application
12.5.7.2.1.
SARS-CoV-2
Diagnosis and Surveillance
12.5.7.2.2.
Post
transplant Subclinical Acute or Acute rejection
12.5.7.2.3.
Solid
Organ Transplant Testing
12.5.7.2.4.
Blood
and Marrow Transplant
12.5.7.2.5.
Others
12.5.7.3.
Benelux
Union Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts,
By End User
12.5.7.3.1.
Hospitals
12.5.7.3.2.
Blood
Banks and Transplant Centers
12.5.7.3.3.
Donor
registries and research laboratories
12.5.7.3.4.
Human leukocyte
antigen (HLA) Laboratories
12.5.7.3.5.
Others
12.5.7.4.
Benelux
Union Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts,
By Country
12.5.7.4.1.
Belgium
12.5.7.4.2.
The
Netherlands
12.5.7.4.3.
Luxembourg
12.5.8. Rest of Europe
12.5.8.1.
Rest of
Europe Serological Transplant Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offering
12.5.8.1.1.
Terasaki
T1
12.5.8.1.2.
HLA
Genotyping
12.5.8.1.2.1. Molecular typing kits
12.5.8.1.2.2. SSP typing and SeCore sequence-based typing
products
12.5.8.1.2.3. Others
12.5.8.1.3.
Antibody
Detection
12.5.8.1.3.1. Screening and identification
12.5.8.1.3.2. Donor specific antibody identification
12.5.8.1.3.3. Single antigen and MICA kits
12.5.8.1.4.
T2
12.5.8.1.5.
T3 NIH
method typing trays and monoclonal trays
12.5.8.1.6.
Specific,
ethnic, Supplemental and dry trays
12.5.8.1.7.
Others
12.5.8.2.
Rest of
Europe Serological Transplant Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Application
12.5.8.2.1.
SARS-CoV-2
Diagnosis and Surveillance
12.5.8.2.2.
Post
transplant Subclinical Acute or Acute rejection
12.5.8.2.3.
Solid
Organ Transplant Testing
12.5.8.2.4.
Blood
and Marrow Transplant
12.5.8.2.5.
Others
12.5.8.3.
Rest of
Europe Serological Transplant Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End User
12.5.8.3.1.
Hospitals
12.5.8.3.2.
Blood
Banks and Transplant Centers
12.5.8.3.3.
Donor
registries and research laboratories
12.5.8.3.4.
Human
leukocyte antigen (HLA) Laboratories
12.5.8.3.5.
Others
12.6. Key Segment for Channeling Investments
12.6.1. By Country
12.6.2. By Offering
12.6.3. By Application
12.6.4. By End User
13. Asia Pacific Serological Transplant
Diagnostics Market Analysis and Forecasts, 2022 - 2030
13.1. Overview
13.1.1. Asia Pacific Serological Transplant
Diagnostics Market Revenue (US$ Mn)
13.2. Asia Pacific Serological Transplant
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offering
13.2.1. Terasaki T1
13.2.2. HLA Genotyping
13.2.2.1.
Molecular
typing kits
13.2.2.2.
SSP
typing and SeCore sequence-based typing products
13.2.2.3.
Others
13.2.3. Antibody Detection
13.2.3.1.
Screening
and identification
13.2.3.2.
Donor
specific antibody identification
13.2.3.3.
Single
antigen and MICA kits
13.2.4. T2
13.2.5. T3 NIH method typing trays and monoclonal
trays
13.2.6. Specific, ethnic, Supplemental and dry trays
13.2.7. Others
13.3. Asia Pacific Serological Transplant
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
13.3.1. SARS-CoV-2 Diagnosis and Surveillance
13.3.2. Post transplant Subclinical Acute or Acute
rejection
13.3.3. Solid Organ Transplant Testing
13.3.4. Blood and Marrow Transplant
13.3.5. Others
13.4. Asia Pacific Serological Transplant
Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
13.4.1. Hospitals
13.4.2. Blood Banks and Transplant Centers
13.4.3. Donor registries and research laboratories
13.4.4. Human leukocyte antigen (HLA) Laboratories
13.4.5. Others
13.5. Asia Pacific Serological Transplant
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
13.5.1. China
13.5.1.1.
China
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Offering
13.5.1.1.1.
Terasaki
T1
13.5.1.1.2.
HLA
Genotyping
13.5.1.1.2.1. Molecular typing kits
13.5.1.1.2.2. SSP typing and SeCore sequence-based typing
products
13.5.1.1.2.3. Others
13.5.1.1.3.
Antibody
Detection
13.5.1.1.3.1. Screening and identification
13.5.1.1.3.2. Donor specific antibody identification
13.5.1.1.3.3. Single antigen and MICA kits
13.5.1.1.4.
T2
13.5.1.1.5.
T3 NIH
method typing trays and monoclonal trays
13.5.1.1.6.
Specific,
ethnic, Supplemental and dry trays
13.5.1.1.7.
Others
13.5.1.2.
China
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
13.5.1.2.1.
SARS-CoV-2
Diagnosis and Surveillance
13.5.1.2.2.
Post
transplant Subclinical Acute or Acute rejection
13.5.1.2.3.
Solid
Organ Transplant Testing
13.5.1.2.4.
Blood
and Marrow Transplant
13.5.1.2.5.
Others
13.5.1.3.
China
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
End User
13.5.1.3.1.
Hospitals
13.5.1.3.2.
Blood
Banks and Transplant Centers
13.5.1.3.3.
Donor
registries and research laboratories
13.5.1.3.4.
Human
leukocyte antigen (HLA) Laboratories
13.5.1.3.5.
Others
13.5.2. Japan
13.5.2.1.
Japan
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Offering
13.5.2.1.1.
Terasaki
T1
13.5.2.1.2.
HLA
Genotyping
13.5.2.1.2.1. Molecular typing kits
13.5.2.1.2.2. SSP typing and SeCore sequence-based typing
products
13.5.2.1.2.3. Others
13.5.2.1.3.
Antibody
Detection
13.5.2.1.3.1. Screening and identification
13.5.2.1.3.2. Donor specific antibody identification
13.5.2.1.3.3. Single antigen and MICA kits
13.5.2.1.4.
T2
13.5.2.1.5.
T3 NIH
method typing trays and monoclonal trays
13.5.2.1.6.
Specific,
ethnic, Supplemental and dry trays
13.5.2.1.7.
Others
13.5.2.2.
Japan
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
13.5.2.2.1.
SARS-CoV-2
Diagnosis and Surveillance
13.5.2.2.2.
Post
transplant Subclinical Acute or Acute rejection
13.5.2.2.3.
Solid
Organ Transplant Testing
13.5.2.2.4.
Blood
and Marrow Transplant
13.5.2.2.5.
Others
13.5.2.3.
Japan
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
End User
13.5.2.3.1.
Hospitals
13.5.2.3.2.
Blood
Banks and Transplant Centers
13.5.2.3.3.
Donor
registries and research laboratories
13.5.2.3.4.
Human
leukocyte antigen (HLA) Laboratories
13.5.2.3.5.
Others
13.5.3. India
13.5.3.1.
India
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Offering
13.5.3.1.1.
Terasaki
T1
13.5.3.1.2.
HLA
Genotyping
13.5.3.1.2.1. Molecular typing kits
13.5.3.1.2.2. SSP typing and SeCore sequence-based typing
products
13.5.3.1.2.3. Others
13.5.3.1.3.
Antibody
Detection
13.5.3.1.3.1. Screening and identification
13.5.3.1.3.2. Donor specific antibody identification
13.5.3.1.3.3. Single antigen and MICA kits
13.5.3.1.4.
T2
13.5.3.1.5.
T3 NIH
method typing trays and monoclonal trays
13.5.3.1.6.
Specific,
ethnic, Supplemental and dry trays
13.5.3.1.7.
Others
13.5.3.2.
India
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
13.5.3.2.1.
SARS-CoV-2
Diagnosis and Surveillance
13.5.3.2.2.
Post
transplant Subclinical Acute or Acute rejection
13.5.3.2.3.
Solid
Organ Transplant Testing
13.5.3.2.4.
Blood
and Marrow Transplant
13.5.3.2.5.
Others
13.5.3.3.
India
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
End User
13.5.3.3.1.
Hospitals
13.5.3.3.2.
Blood
Banks and Transplant Centers
13.5.3.3.3.
Donor
registries and research laboratories
13.5.3.3.4.
Human
leukocyte antigen (HLA) Laboratories
13.5.3.3.5.
Others
13.5.4. New Zealand
13.5.4.1.
New
Zealand Serological Transplant Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offering
13.5.4.1.1.
Terasaki
T1
13.5.4.1.2.
HLA
Genotyping
13.5.4.1.2.1. Molecular typing kits
13.5.4.1.2.2. SSP typing and SeCore sequence-based typing
products
13.5.4.1.2.3. Others
13.5.4.1.3.
Antibody
Detection
13.5.4.1.3.1. Screening and identification
13.5.4.1.3.2. Donor specific antibody identification
13.5.4.1.3.3. Single antigen and MICA kits
13.5.4.1.4.
T2
13.5.4.1.5.
T3 NIH
method typing trays and monoclonal trays
13.5.4.1.6.
Specific,
ethnic, Supplemental and dry trays
13.5.4.1.7.
Others
13.5.4.2.
New
Zealand Serological Transplant Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Application
13.5.4.2.1.
SARS-CoV-2
Diagnosis and Surveillance
13.5.4.2.2.
Post
transplant Subclinical Acute or Acute rejection
13.5.4.2.3.
Solid
Organ Transplant Testing
13.5.4.2.4.
Blood
and Marrow Transplant
13.5.4.2.5.
Others
13.5.4.3.
New
Zealand Serological Transplant Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End User
13.5.4.3.1.
Hospitals
13.5.4.3.2.
Blood
Banks and Transplant Centers
13.5.4.3.3.
Donor
registries and research laboratories
13.5.4.3.4.
Human
leukocyte antigen (HLA) Laboratories
13.5.4.3.5.
Others
13.5.5. Australia
13.5.5.1.
Australia
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Offering
13.5.5.1.1.
Terasaki
T1
13.5.5.1.2.
HLA
Genotyping
13.5.5.1.2.1. Molecular typing kits
13.5.5.1.2.2. SSP typing and SeCore sequence-based typing
products
13.5.5.1.2.3. Others
13.5.5.1.3.
Antibody
Detection
13.5.5.1.3.1. Screening and identification
13.5.5.1.3.2. Donor specific antibody identification
13.5.5.1.3.3. Single antigen and MICA kits
13.5.5.1.4.
T2
13.5.5.1.5.
T3 NIH
method typing trays and monoclonal trays
13.5.5.1.6.
Specific,
ethnic, Supplemental and dry trays
13.5.5.1.7.
Others
13.5.5.2.
Australia
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
13.5.5.2.1.
SARS-CoV-2
Diagnosis and Surveillance
13.5.5.2.2.
Post
transplant Subclinical Acute or Acute rejection
13.5.5.2.3.
Solid
Organ Transplant Testing
13.5.5.2.4.
Blood
and Marrow Transplant
13.5.5.2.5.
Others
13.5.5.3.
Australia
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
End User
13.5.5.3.1.
Hospitals
13.5.5.3.2.
Blood
Banks and Transplant Centers
13.5.5.3.3.
Donor
registries and research laboratories
13.5.5.3.4.
Human
leukocyte antigen (HLA) Laboratories
13.5.5.3.5.
Others
13.5.6. South Korea
13.5.6.1.
South
Korea Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts,
By Offering
13.5.6.1.1.
Terasaki
T1
13.5.6.1.2.
HLA
Genotyping
13.5.6.1.2.1. Molecular typing kits
13.5.6.1.2.2. SSP typing and SeCore sequence-based typing
products
13.5.6.1.2.3. Others
13.5.6.1.3.
Antibody
Detection
13.5.6.1.3.1. Screening and identification
13.5.6.1.3.2. Donor specific antibody identification
13.5.6.1.3.3. Single antigen and MICA kits
13.5.6.1.4.
T2
13.5.6.1.5.
T3 NIH method
typing trays and monoclonal trays
13.5.6.1.6.
Specific,
ethnic, Supplemental and dry trays
13.5.6.1.7.
Others
13.5.6.2.
South
Korea Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts,
By Application
13.5.6.2.1.
SARS-CoV-2
Diagnosis and Surveillance
13.5.6.2.2.
Post
transplant Subclinical Acute or Acute rejection
13.5.6.2.3.
Solid
Organ Transplant Testing
13.5.6.2.4.
Blood
and Marrow Transplant
13.5.6.2.5.
Others
13.5.6.3.
South
Korea Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts,
By End User
13.5.6.3.1.
Hospitals
13.5.6.3.2.
Blood
Banks and Transplant Centers
13.5.6.3.3.
Donor
registries and research laboratories
13.5.6.3.4.
Human
leukocyte antigen (HLA) Laboratories
13.5.6.3.5.
Others
13.5.7. Southeast Asia
13.5.7.1.
Southeast
Asia Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts,
By Offering
13.5.7.1.1.
Terasaki
T1
13.5.7.1.2.
HLA
Genotyping
13.5.7.1.2.1. Molecular typing kits
13.5.7.1.2.2. SSP typing and SeCore sequence-based typing
products
13.5.7.1.2.3. Others
13.5.7.1.3.
Antibody
Detection
13.5.7.1.3.1. Screening and identification
13.5.7.1.3.2. Donor specific antibody identification
13.5.7.1.3.3. Single antigen and MICA kits
13.5.7.1.4.
T2
13.5.7.1.5.
T3 NIH
method typing trays and monoclonal trays
13.5.7.1.6.
Specific,
ethnic, Supplemental and dry trays
13.5.7.1.7.
Others
13.5.7.2.
Southeast
Asia Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts,
By Application
13.5.7.2.1.
SARS-CoV-2
Diagnosis and Surveillance
13.5.7.2.2.
Post
transplant Subclinical Acute or Acute rejection
13.5.7.2.3.
Solid
Organ Transplant Testing
13.5.7.2.4.
Blood
and Marrow Transplant
13.5.7.2.5.
Others
13.5.7.3.
Southeast
Asia Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts,
By End User
13.5.7.3.1.
Hospitals
13.5.7.3.2.
Blood
Banks and Transplant Centers
13.5.7.3.3.
Donor
registries and research laboratories
13.5.7.3.4.
Human
leukocyte antigen (HLA) Laboratories
13.5.7.3.5.
Others
13.5.7.4.
Southeast
Asia Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts,
By Country
13.5.7.4.1.
Indonesia
13.5.7.4.2.
Thailand
13.5.7.4.3.
Malaysia
13.5.7.4.4.
Singapore
13.5.7.4.5.
Rest of
Southeast Asia
13.5.8. Rest of Asia Pacific
13.5.8.1.
Rest of
Asia Pacific Serological Transplant Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offering
13.5.8.1.1.
Terasaki
T1
13.5.8.1.2.
HLA
Genotyping
13.5.8.1.2.1. Molecular typing kits
13.5.8.1.2.2. SSP typing and SeCore sequence-based typing
products
13.5.8.1.2.3. Others
13.5.8.1.3.
Antibody
Detection
13.5.8.1.3.1. Screening and identification
13.5.8.1.3.2. Donor specific antibody identification
13.5.8.1.3.3. Single antigen and MICA kits
13.5.8.1.4.
T2
13.5.8.1.5.
T3 NIH
method typing trays and monoclonal trays
13.5.8.1.6.
Specific,
ethnic, Supplemental and dry trays
13.5.8.1.7.
Others
13.5.8.2.
Rest of
Asia Pacific Serological Transplant Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Application
13.5.8.2.1.
SARS-CoV-2
Diagnosis and Surveillance
13.5.8.2.2.
Post transplant
Subclinical Acute or Acute rejection
13.5.8.2.3.
Solid
Organ Transplant Testing
13.5.8.2.4.
Blood
and Marrow Transplant
13.5.8.2.5.
Others
13.5.8.3.
Rest of
Asia Pacific Serological Transplant Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End User
13.5.8.3.1.
Hospitals
13.5.8.3.2.
Blood
Banks and Transplant Centers
13.5.8.3.3.
Donor
registries and research laboratories
13.5.8.3.4.
Human
leukocyte antigen (HLA) Laboratories
13.5.8.3.5.
Others
13.6. Key Segment for Channeling Investments
13.6.1. By Country
13.6.2. By Offering
13.6.3. By Application
13.6.4. By End User
14. Middle East and Africa Serological
Transplant Diagnostics Market Analysis and Forecasts, 2022 - 2030
14.1. Overview
14.1.1. Middle East and Africa Serological Transplant
Diagnostics Market Revenue (US$ Mn)
14.2. Middle East and Africa Serological Transplant
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offering
14.2.1. Terasaki T1
14.2.2. HLA Genotyping
14.2.2.1.
Molecular
typing kits
14.2.2.2.
SSP
typing and SeCore sequence-based typing products
14.2.2.3.
Others
14.2.3. Antibody Detection
14.2.3.1.
Screening
and identification
14.2.3.2.
Donor
specific antibody identification
14.2.3.3.
Single
antigen and MICA kits
14.2.4. T2
14.2.5. T3 NIH method typing trays and monoclonal
trays
14.2.6. Specific, ethnic, Supplemental and dry trays
14.2.7. Others
14.3. Middle East and Africa Serological Transplant
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
14.3.1. SARS-CoV-2 Diagnosis and Surveillance
14.3.2. Post transplant Subclinical Acute or Acute
rejection
14.3.3. Solid Organ Transplant Testing
14.3.4. Blood and Marrow Transplant
14.3.5. Others
14.4. Middle East and Africa Serological Transplant
Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
14.4.1. Hospitals
14.4.2. Blood Banks and Transplant Centers
14.4.3. Donor registries and research laboratories
14.4.4. Human leukocyte antigen (HLA) Laboratories
14.4.5. Others
14.5. Middle East and Africa Serological Transplant
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
14.5.1. Saudi Arabia
14.5.1.1.
Saudi
Arabia Serological Transplant Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offering
14.5.1.1.1.
Terasaki
T1
14.5.1.1.2.
HLA
Genotyping
14.5.1.1.2.1. Molecular typing kits
14.5.1.1.2.2. SSP typing and SeCore sequence-based typing
products
14.5.1.1.2.3. Others
14.5.1.1.3.
Antibody
Detection
14.5.1.1.3.1. Screening and identification
14.5.1.1.3.2. Donor specific antibody identification
14.5.1.1.3.3. Single antigen and MICA kits
14.5.1.1.4.
T2
14.5.1.1.5.
T3 NIH
method typing trays and monoclonal trays
14.5.1.1.6.
Specific,
ethnic, Supplemental and dry trays
14.5.1.1.7.
Others
14.5.1.2.
Saudi
Arabia Serological Transplant Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Application
14.5.1.2.1.
SARS-CoV-2
Diagnosis and Surveillance
14.5.1.2.2.
Post
transplant Subclinical Acute or Acute rejection
14.5.1.2.3.
Solid
Organ Transplant Testing
14.5.1.2.4.
Blood
and Marrow Transplant
14.5.1.2.5.
Others
14.5.1.3.
Saudi
Arabia Serological Transplant Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End User
14.5.1.3.1.
Hospitals
14.5.1.3.2.
Blood
Banks and Transplant Centers
14.5.1.3.3.
Donor
registries and research laboratories
14.5.1.3.4.
Human
leukocyte antigen (HLA) Laboratories
14.5.1.3.5.
Others
14.5.2. UAE
14.5.2.1.
UAE
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Offering
14.5.2.1.1.
Terasaki
T1
14.5.2.1.2.
HLA Genotyping
14.5.2.1.2.1. Molecular typing kits
14.5.2.1.2.2. SSP typing and SeCore sequence-based typing
products
14.5.2.1.2.3. Others
14.5.2.1.3.
Antibody
Detection
14.5.2.1.3.1. Screening and identification
14.5.2.1.3.2. Donor specific antibody identification
14.5.2.1.3.3. Single antigen and MICA kits
14.5.2.1.4.
T2
14.5.2.1.5.
T3 NIH
method typing trays and monoclonal trays
14.5.2.1.6.
Specific,
ethnic, Supplemental and dry trays
14.5.2.1.7.
Others
14.5.2.2.
UAE
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
14.5.2.2.1.
SARS-CoV-2
Diagnosis and Surveillance
14.5.2.2.2.
Post
transplant Subclinical Acute or Acute rejection
14.5.2.2.3.
Solid
Organ Transplant Testing
14.5.2.2.4.
Blood
and Marrow Transplant
14.5.2.2.5.
Others
14.5.2.3.
UAE
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
End User
14.5.2.3.1.
Hospitals
14.5.2.3.2.
Blood
Banks and Transplant Centers
14.5.2.3.3.
Donor
registries and research laboratories
14.5.2.3.4.
Human
leukocyte antigen (HLA) Laboratories
14.5.2.3.5.
Others
14.5.3. Egypt
14.5.3.1.
Egypt
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Offering
14.5.3.1.1.
Terasaki
T1
14.5.3.1.2.
HLA
Genotyping
14.5.3.1.2.1. Molecular typing kits
14.5.3.1.2.2. SSP typing and SeCore sequence-based typing
products
14.5.3.1.2.3. Others
14.5.3.1.3.
Antibody
Detection
14.5.3.1.3.1. Screening and identification
14.5.3.1.3.2. Donor specific antibody identification
14.5.3.1.3.3. Single antigen and MICA kits
14.5.3.1.4.
T2
14.5.3.1.5.
T3 NIH
method typing trays and monoclonal trays
14.5.3.1.6.
Specific,
ethnic, Supplemental and dry trays
14.5.3.1.7.
Others
14.5.3.2.
Egypt
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
14.5.3.2.1.
SARS-CoV-2
Diagnosis and Surveillance
14.5.3.2.2.
Post
transplant Subclinical Acute or Acute rejection
14.5.3.2.3.
Solid
Organ Transplant Testing
14.5.3.2.4.
Blood
and Marrow Transplant
14.5.3.2.5.
Others
14.5.3.3.
Egypt
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
End User
14.5.3.3.1.
Hospitals
14.5.3.3.2.
Blood
Banks and Transplant Centers
14.5.3.3.3.
Donor
registries and research laboratories
14.5.3.3.4.
Human
leukocyte antigen (HLA) Laboratories
14.5.3.3.5.
Others
14.5.4. Kuwait
14.5.4.1.
Kuwait
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Offering
14.5.4.1.1.
Terasaki
T1
14.5.4.1.2.
HLA
Genotyping
14.5.4.1.2.1. Molecular typing kits
14.5.4.1.2.2. SSP typing and SeCore sequence-based typing
products
14.5.4.1.2.3. Others
14.5.4.1.3.
Antibody
Detection
14.5.4.1.3.1. Screening and identification
14.5.4.1.3.2. Donor specific antibody identification
14.5.4.1.3.3. Single antigen and MICA kits
14.5.4.1.4.
T2
14.5.4.1.5.
T3 NIH
method typing trays and monoclonal trays
14.5.4.1.6.
Specific,
ethnic, Supplemental and dry trays
14.5.4.1.7.
Others
14.5.4.2.
Kuwait
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
14.5.4.2.1.
SARS-CoV-2
Diagnosis and Surveillance
14.5.4.2.2.
Post
transplant Subclinical Acute or Acute rejection
14.5.4.2.3.
Solid
Organ Transplant Testing
14.5.4.2.4.
Blood
and Marrow Transplant
14.5.4.2.5.
Others
14.5.4.3.
Kuwait
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
End User
14.5.4.3.1.
Hospitals
14.5.4.3.2.
Blood
Banks and Transplant Centers
14.5.4.3.3.
Donor
registries and research laboratories
14.5.4.3.4.
Human
leukocyte antigen (HLA) Laboratories
14.5.4.3.5.
Others
14.5.5. South Africa
14.5.5.1.
South
Africa Serological Transplant Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offering
14.5.5.1.1.
Terasaki
T1
14.5.5.1.2.
HLA
Genotyping
14.5.5.1.2.1. Molecular typing kits
14.5.5.1.2.2. SSP typing and SeCore sequence-based typing products
14.5.5.1.2.3. Others
14.5.5.1.3.
Antibody
Detection
14.5.5.1.3.1. Screening and identification
14.5.5.1.3.2. Donor specific antibody identification
14.5.5.1.3.3. Single antigen and MICA kits
14.5.5.1.4.
T2
14.5.5.1.5.
T3 NIH
method typing trays and monoclonal trays
14.5.5.1.6.
Specific,
ethnic, Supplemental and dry trays
14.5.5.1.7.
Others
14.5.5.2.
South
Africa Serological Transplant Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Application
14.5.5.2.1.
SARS-CoV-2
Diagnosis and Surveillance
14.5.5.2.2.
Post
transplant Subclinical Acute or Acute rejection
14.5.5.2.3.
Solid
Organ Transplant Testing
14.5.5.2.4.
Blood
and Marrow Transplant
14.5.5.2.5.
Others
14.5.5.3.
South
Africa Serological Transplant Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End User
14.5.5.3.1.
Hospitals
14.5.5.3.2.
Blood
Banks and Transplant Centers
14.5.5.3.3.
Donor
registries and research laboratories
14.5.5.3.4.
Human
leukocyte antigen (HLA) Laboratories
14.5.5.3.5.
Others
14.5.6. Rest of Middle East & Africa
14.5.6.1.
Rest of
Middle East & Africa Serological Transplant Diagnostics Market Revenue (US$
Mn) and Forecasts, By Offering
14.5.6.1.1.
Terasaki
T1
14.5.6.1.2.
HLA
Genotyping
14.5.6.1.2.1. Molecular typing kits
14.5.6.1.2.2. SSP typing and SeCore sequence-based typing
products
14.5.6.1.2.3. Others
14.5.6.1.3.
Antibody
Detection
14.5.6.1.3.1. Screening and identification
14.5.6.1.3.2. Donor specific antibody identification
14.5.6.1.3.3. Single antigen and MICA kits
14.5.6.1.4.
T2
14.5.6.1.5.
T3 NIH
method typing trays and monoclonal trays
14.5.6.1.6.
Specific,
ethnic, Supplemental and dry trays
14.5.6.1.7.
Others
14.5.6.2.
Rest of
Middle East & Africa Serological Transplant Diagnostics Market Revenue (US$
Mn) and Forecasts, By Application
14.5.6.2.1.
SARS-CoV-2
Diagnosis and Surveillance
14.5.6.2.2.
Post
transplant Subclinical Acute or Acute rejection
14.5.6.2.3.
Solid
Organ Transplant Testing
14.5.6.2.4.
Blood
and Marrow Transplant
14.5.6.2.5.
Others
14.5.6.3.
Rest of
Middle East & Africa Serological Transplant Diagnostics Market Revenue (US$
Mn) and Forecasts, By End User
14.5.6.3.1.
Hospitals
14.5.6.3.2.
Blood
Banks and Transplant Centers
14.5.6.3.3.
Donor
registries and research laboratories
14.5.6.3.4.
Human
leukocyte antigen (HLA) Laboratories
14.5.6.3.5.
Others
14.6. Key Segment for Channeling Investments
14.6.1. By Country
14.6.2. By Offering
14.6.3. By Application
14.6.4. By End User
15. Latin America Serological Transplant
Diagnostics Market Analysis and Forecasts, 2022 - 2030
15.1. Overview
15.1.1. Latin America Serological Transplant
Diagnostics Market Revenue (US$ Mn)
15.2. Latin America Serological Transplant
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offering
15.2.1. Terasaki T1
15.2.2. HLA Genotyping
15.2.2.1.
Molecular
typing kits
15.2.2.2.
SSP
typing and SeCore sequence-based typing products
15.2.2.3.
Others
15.2.3. Antibody Detection
15.2.3.1.
Screening
and identification
15.2.3.2.
Donor
specific antibody identification
15.2.3.3.
Single antigen
and MICA kits
15.2.4. T2
15.2.5. T3 NIH method typing trays and monoclonal
trays
15.2.6. Specific, ethnic, Supplemental and dry trays
15.2.7. Others
15.3. Latin America Serological Transplant
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
15.3.1. SARS-CoV-2 Diagnosis and Surveillance
15.3.2. Post transplant Subclinical Acute or Acute
rejection
15.3.3. Solid Organ Transplant Testing
15.3.4. Blood and Marrow Transplant
15.3.5. Others
15.4. Latin America Serological Transplant
Diagnostics Market Revenue (US$ Mn) and Forecasts, By End User
15.4.1. Hospitals
15.4.2. Blood Banks and Transplant Centers
15.4.3. Donor registries and research laboratories
15.4.4. Human leukocyte antigen (HLA) Laboratories
15.4.5. Others
15.5. Latin America Serological Transplant
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1.
Brazil
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Offering
15.5.1.1.1.
Terasaki
T1
15.5.1.1.2.
HLA
Genotyping
15.5.1.1.2.1. Molecular typing kits
15.5.1.1.2.2. SSP typing and SeCore sequence-based typing
products
15.5.1.1.2.3. Others
15.5.1.1.3.
Antibody
Detection
15.5.1.1.3.1. Screening and identification
15.5.1.1.3.2. Donor specific antibody identification
15.5.1.1.3.3. Single antigen and MICA kits
15.5.1.1.4.
T2
15.5.1.1.5.
T3 NIH
method typing trays and monoclonal trays
15.5.1.1.6.
Specific,
ethnic, Supplemental and dry trays
15.5.1.1.7.
Others
15.5.1.2.
Brazil
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
15.5.1.2.1.
SARS-CoV-2
Diagnosis and Surveillance
15.5.1.2.2.
Post
transplant Subclinical Acute or Acute rejection
15.5.1.2.3.
Solid
Organ Transplant Testing
15.5.1.2.4.
Blood
and Marrow Transplant
15.5.1.2.5.
Others
15.5.1.3.
Brazil
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
End User
15.5.1.3.1.
Hospitals
15.5.1.3.2.
Blood
Banks and Transplant Centers
15.5.1.3.3.
Donor
registries and research laboratories
15.5.1.3.4.
Human
leukocyte antigen (HLA) Laboratories
15.5.1.3.5.
Others
15.5.2. Argentina
15.5.2.1.
Argentina
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Offering
15.5.2.1.1.
Terasaki
T1
15.5.2.1.2.
HLA
Genotyping
15.5.2.1.2.1. Molecular typing kits
15.5.2.1.2.2. SSP typing and SeCore sequence-based typing
products
15.5.2.1.2.3. Others
15.5.2.1.3.
Antibody
Detection
15.5.2.1.3.1. Screening and identification
15.5.2.1.3.2. Donor specific antibody identification
15.5.2.1.3.3. Single antigen and MICA kits
15.5.2.1.4.
T2
15.5.2.1.5.
T3 NIH
method typing trays and monoclonal trays
15.5.2.1.6.
Specific,
ethnic, Supplemental and dry trays
15.5.2.1.7.
Others
15.5.2.2.
Argentina
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
15.5.2.2.1.
SARS-CoV-2
Diagnosis and Surveillance
15.5.2.2.2.
Post
transplant Subclinical Acute or Acute rejection
15.5.2.2.3.
Solid
Organ Transplant Testing
15.5.2.2.4.
Blood
and Marrow Transplant
15.5.2.2.5.
Others
15.5.2.3.
Argentina
Serological Transplant Diagnostics Market Revenue (US$ Mn) and Forecasts, By
End User
15.5.2.3.1.
Hospitals
15.5.2.3.2.
Blood
Banks and Transplant Centers
15.5.2.3.3.
Donor
registries and research laboratories
15.5.2.3.4.
Human
leukocyte antigen (HLA) Laboratories
15.5.2.3.5.
Others
15.5.3. Rest of Latin America
15.5.3.1.
Rest of
Latin America Serological Transplant Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Offering
15.5.3.1.1.
Terasaki
T1
15.5.3.1.2.
HLA
Genotyping
15.5.3.1.2.1. Molecular typing kits
15.5.3.1.2.2. SSP typing and SeCore sequence-based typing
products
15.5.3.1.2.3. Others
15.5.3.1.3.
Antibody
Detection
15.5.3.1.3.1. Screening and identification
15.5.3.1.3.2. Donor specific antibody identification
15.5.3.1.3.3. Single antigen and MICA kits
15.5.3.1.4.
T2
15.5.3.1.5.
T3 NIH
method typing trays and monoclonal trays
15.5.3.1.6.
Specific,
ethnic, Supplemental and dry trays
15.5.3.1.7.
Others
15.5.3.2.
Rest of
Latin America Serological Transplant Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Application
15.5.3.2.1.
SARS-CoV-2
Diagnosis and Surveillance
15.5.3.2.2.
Post
transplant Subclinical Acute or Acute rejection
15.5.3.2.3.
Solid
Organ Transplant Testing
15.5.3.2.4.
Blood
and Marrow Transplant
15.5.3.2.5.
Others
15.5.3.3.
Rest of
Latin America Serological Transplant Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End User
15.5.3.3.1.
Hospitals
15.5.3.3.2.
Blood
Banks and Transplant Centers
15.5.3.3.3.
Donor
registries and research laboratories
15.5.3.3.4.
Human
leukocyte antigen (HLA) Laboratories
15.5.3.3.5.
Others
15.6. Key Segment for Channeling Investments
15.6.1. By Country
15.6.2. By Offering
15.6.3. By Application
15.6.4. By End User
16. Competitive Benchmarking
16.1. Brand Benchmarking
16.2. Market Share Analysis, 2021
16.3. Global Presence and Growth Strategies
16.3.1. Mergers and Acquisitions
16.3.2. Product Launches
16.3.3. Investments Trends
16.3.4. R&D Initiatives
17. Player Profiles
17.1. Agena Bioscience
17.1.2. Company Overview
17.1.3. Product Offerings
17.1.4. Key Developments
17.1.5. Financial Analysis
17.1.6. SWOT Analysis
17.1.7. Business Strategies
17.2. AVIOQ
17.2.1. Company Details
17.2.2. Company Overview
17.2.3. Product Offerings
17.2.4. Key Developments
17.2.5. Financial Analysis
17.2.6. SWOT Analysis
17.2.7. Business Strategies
17.3. BAG Healthcare
17.3.1. Company Details
17.3.2. Company Overview
17.3.3. Product Offerings
17.3.4. Key Developments
17.3.5. Financial Analysis
17.3.6. SWOT Analysis
17.3.7. Business Strategies
17.4. BD
17.4.1. Company Details
17.4.2. Company Overview
17.4.3. Product Offerings
17.4.4. Key Developments
17.4.5. Financial Analysis
17.4.6. SWOT Analysis
17.4.7. Business Strategies
17.5. Beckman Coulter
17.5.1. Company Details
17.5.2. Company Overview
17.5.3. Product Offerings
17.5.4. Key Developments
17.5.5. Financial Analysis
17.5.6. SWOT Analysis
17.5.7. Business Strategies
17.6. Biogenuix
17.6.1. Company Details
17.6.2. Company Overview
17.6.3. Product Offerings
17.6.4. Key Developments
17.6.5. Financial Analysis
17.6.6. SWOT Analysis
17.6.7. Business Strategies
17.7. Bio-Rad Laboratories, Inc.
17.7.1. Company Details
17.7.2. Company Overview
17.7.3. Product Offerings
17.7.4. Key Developments
17.7.5. Financial Analysis
17.7.6. SWOT Analysis
17.7.7. Business Strategies
17.8. DIAGAST
17.8.1. Company Details
17.8.2. Company Overview
17.8.3. Product Offerings
17.8.4. Key Developments
17.8.5. Financial Analysis
17.8.6. SWOT Analysis
17.8.7. Business Strategies
17.9. Grifols
17.9.1. Company Details
17.9.2. Company Overview
17.9.3. Product Offerings
17.9.4. Key Developments
17.9.5. Financial Analysis
17.9.6. SWOT Analysis
17.9.7. Business Strategies
17.10. Hemo bioscience
17.10.1. Company Details
17.10.2. Company Overview
17.10.3. Product Offerings
17.10.4. Key Developments
17.10.5. Financial Analysis
17.10.6. SWOT Analysis
17.10.7. Business Strategies
17.11. Immucor
17.11.1. Company Details
17.11.2. Company Overview
17.11.3. Product Offerings
17.11.4. Key Developments
17.11.5. Financial Analysis
17.11.6. SWOT Analysis
17.11.7. Business Strategies
17.12. Siemens Healthineers
17.12.1. Company Details
17.12.2. Company Overview
17.12.3. Product Offerings
17.12.4. Key Developments
17.12.5. Financial Analysis
17.12.6. SWOT Analysis
17.12.7. Business Strategies
17.13. ThermoFisher Scientific
17.13.1. Company Details
17.13.2. Company Overview
17.13.3. Product Offerings
17.13.4. Key Developments
17.13.5. Financial Analysis
17.13.6. SWOT Analysis
17.13.7. Business Strategies
17.14. Other Market Participants
18. Key Findings
Note: This ToC is tentative and can be changed according to the research study conducted during the course of
report completion.
**Exclusive for Multi-User and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.